False Hope? Managing Pressure to Provide Experimental Therapy

Richard A. Rettig, Ph.D.
RAND Corporation

1:15 p.m., Friday, March 9, 2007 [note variant time]
Mailman Center for Child Development, Room 3023

The use of bone marrow transplantation for breast cancer created a conflict between patient demand (reinforced by physician enthusiasm, litigation, media accounts, government mandates and entrepreneurial oncology) for access to a “promising” new treatment for breast cancer and the need for evaluation of that promise in randomized clinical trials. There is a tension between protecting the evaluative enterprise and providing a safety valve for responding to the legitimate needs of individual women. Pressure to provide poorly evaluated treatments can imperil patients and frustrate clinicians.

Dr. Rettig, a Senior Social Scientist at the RAND Corporation and a former professional staff member of the Institute of Medicine, has written extensively on clinical research, technology assessment in medicine, organ transplantation and end-stage renal disease. He is co-author of *False Hope: Bone Marrow Transplantation for Breast Cancer* (Oxford 2007), which documents the failure of the treatment.

Dialogues in Research Ethics is a series of monthly conferences. For more information, phone UM Ethics Programs at 305-243-5723 or send E-mail to ethics@miami.edu.

Co-sponsors:
- Vice Provost for Research
- Jackson Health System/Public Health Trust
- Office of Graduate Studies
- Research Service of the Miami VA Healthcare System
- Department of Molecular and Cellular Pharmacology
- Mailman Center for Child Development